Emergency, Trauma, Acute Care & Surgical Critical Care

Perform immediate biphasic CT angiography (arterial + portal venous phases) at first suspicion ('pain out of proportion'); give systemic unfractionated heparin; and follow a revascularization-first strategy (endovascular aspiration thrombectomy/angioplasty or open superior mesenteric artery embolectomy/bypass) BEFORE resecting borderline bowel. Apply damage-control stapling to frankly necrotic bowel with an open abdomen and a mandatory planned second-look laparotomy at 24–48 hours, using ICG fluorescence.

Before: Delayed diagnosis waiting for lactic acidosis or peritonitis, or upfront extensive bowel resection and stoma creation before restoring mesenteric arterial inflow.

Now: Perform immediate biphasic CT angiography (arterial + portal venous phases) at first suspicion ('pain out of proportion'); give systemic unfractionated heparin; and follow a revascularization-first strategy (endovascular aspiration thrombectomy/angioplasty or open superior mesenteric artery embolectomy/bypass) BEFORE resecting borderline bowel. Apply damage-control stapling to frankly necrotic bowel with an open abdomen and a mandatory planned second-look laparotomy at 24–48 hours, using ICG fluorescence.

Patients with suspected acute mesenteric ischemia — arterial embolism, atherosclerotic thrombosis, non-occlusive mesenteric ischemia (NOMI), or mesenteric venous thrombosis — exactly as the addendum's summary row states them.

Restoring SMA inflow before bowel resection salvages borderline ischemic intestine and prevents short-bowel syndrome; the planned 24–48 h second-look laparotomy identifies demarcation accurately — resection-first sequencing is the harm this change removes.

• WSES 2022 Acute Mesenteric Ischemia Guidelines — Bala M et al., World J Emerg Surg 2022 (PMID 36261857; Ref. 99)
• ESVS Mesenteric Guidelines — as cited in the addendum summary table (no PMID printed)

Fournier's gangrene: immediate resuscitative broad-spectrum IV antimicrobials (carbapenem or piperacillin-tazobactam + vancomycin + clindamycin for toxin suppression; hold SGLT2 inhibitors immediately) and emergency surgical debridement of all necrotic fascia/skin within hours, sparing the testes (supplied by the internal spermatic arteries), with planned 24-hour re-exploration and NPWT/delayed scrotal reconstruction. Acute testicular torsion (high TWIST score >=5: hard testis, absent cremasteric reflex, high-riding testis, nausea/vomiting, <6 hours onset): immediate surgical scrotal exploration, detorsion, and bilateral 3-point dartos-pouch orchidopexy, without delaying for imaging.

Before: Delaying operative debridement of Fournier's gangrene for CT/MRI, or delaying scrotal exploration for Doppler ultrasound when the clinical TWIST score is high for testicular torsion.

Now: Fournier's gangrene: immediate resuscitative broad-spectrum IV antimicrobials (carbapenem or piperacillin-tazobactam + vancomycin + clindamycin for toxin suppression; hold SGLT2 inhibitors immediately) and emergency surgical debridement of all necrotic fascia/skin within hours, sparing the testes (supplied by the internal spermatic arteries), with planned 24-hour re-exploration and NPWT/delayed scrotal reconstruction. Acute testicular torsion (high TWIST score >=5: hard testis, absent cremasteric reflex, high-riding testis, nausea/vomiting, <6 hours onset): immediate surgical scrotal exploration, detorsion, and bilateral 3-point dartos-pouch orchidopexy, without delaying for imaging.

Patients with Fournier's gangrene (necrotizing perineal/scrotal fasciitis) and patients with acute scrotal emergencies — suspected testicular torsion with a high TWIST score — exactly as the addendum's summary row states them.

Every hour of delayed debridement in Fournier's gangrene escalates mortality (20–40%). In testicular torsion, testicular salvage is >90% at <6 hours, dropping to <50% at 12 hours and <10% after 24 hours — imaging that delays either operation is the harm this change removes. The no-imaging rule is printed for the high-TWIST presentation; it is not generalised here beyond the row's stated population.

• WSES Necrotizing Soft-Tissue Infection Guidelines — as cited in the addendum summary table (no PMID printed)
• EAU / AUA Acute Scrotum Guidelines — as cited in the addendum summary table (no PMID printed)

Perform copious high-pressure normal saline irrigation and sharp debridement of devitalized tissue. Leave deep puncture wounds, all cat bites, hand/foot bites, human clenched-fist ('fight bite' over the MCP joint), and wounds >12 hours old OPEN (facial lacerations may undergo loose primary closure after thorough irrigation). Administer amoxicillin-clavulanate (875/125 mg PO BID for 3–5 days prophylaxis or 7–10 days treatment — covering Pasteurella multocida, Capnocytophaga, Eikenella, and anaerobes), update tetanus toxoid, and administer Rabies Immune Globulin (20 IU/kg infiltrated around the wound) plus inactivated rabies vaccine on Days 0, 3, 7, and 14 per WHO/Saudi MOH protocol.

Before: Tight primary suture closure of deep punctured cat bites or hand bites, or omitting rabies immunoglobulin (RIG) infiltration in severe stray animal bites.

Now: Perform copious high-pressure normal saline irrigation and sharp debridement of devitalized tissue. Leave deep puncture wounds, all cat bites, hand/foot bites, human clenched-fist ('fight bite' over the MCP joint), and wounds >12 hours old OPEN (facial lacerations may undergo loose primary closure after thorough irrigation). Administer amoxicillin-clavulanate (875/125 mg PO BID for 3–5 days prophylaxis or 7–10 days treatment — covering Pasteurella multocida, Capnocytophaga, Eikenella, and anaerobes), update tetanus toxoid, and administer Rabies Immune Globulin (20 IU/kg infiltrated around the wound) plus inactivated rabies vaccine on Days 0, 3, 7, and 14 per WHO/Saudi MOH protocol.

Patients with mammalian bite wounds — cat, dog, camel, and human clenched-fist injuries — exactly as the addendum's summary row states them.

Cat bites penetrate periosteum and tenosynovial sheaths, with >50–80% Pasteurella multocida infection risk if sutured closed. Camel bites in the Arabian Peninsula cause severe crush-avulsion injuries requiring debridement and vascular/fracture check (printed in the row's rationale — carried here, not generalised into a regionalCheck). The facial-laceration loose-closure exception is part of the printed standard.

• IDSA Skin & Soft-Tissue Infection Guidelines — as cited in the addendum summary table (no PMID printed)
• WHO / Saudi MOH Rabies PEP Guidelines — as cited in the addendum summary table (no PMID printed)

Insert a 28–32 Fr chest tube in the 4th/5th intercostal space, anterior-to-mid-axillary line (triangle of safety), for acute traumatic hemothorax (a 14 Fr pigtail catheter is effective for simple pneumothorax or stable non-emergent hemothorax). If post-drainage chest CT shows a retained hemothorax (>300–500 mL or occupying >1/3 of the hemithorax), perform early video-assisted thoracoscopic surgery (VATS) evacuation within <=3–5 days (or intrapleural tPA + DNase in non-operative candidates).

Before: Routine insertion of massive 36–40 Fr chest tubes, or placing a second chest tube / delaying thoracoscopy >7–10 days for a retained clotted hemothorax.

Now: Insert a 28–32 Fr chest tube in the 4th/5th intercostal space, anterior-to-mid-axillary line (triangle of safety), for acute traumatic hemothorax (a 14 Fr pigtail catheter is effective for simple pneumothorax or stable non-emergent hemothorax). If post-drainage chest CT shows a retained hemothorax (>300–500 mL or occupying >1/3 of the hemithorax), perform early video-assisted thoracoscopic surgery (VATS) evacuation within <=3–5 days (or intrapleural tPA + DNase in non-operative candidates).

Patients with traumatic hemothorax/pneumothorax requiring tube thoracostomy, and patients with a retained hemothorax on post-drainage CT, exactly as the addendum's summary row states the thresholds.

28–32 Fr tubes achieve equivalent drainage to 36–40 Fr tubes with significantly less insertion pain. Early VATS within <=4 days reduces post-traumatic empyema (from ~25% to <5%), conversion to open thoracotomy decortication, and hospital stay — delay beyond the printed window forfeits that benefit.

• EAST / WTA Retained Hemothorax Guidelines — as cited in the addendum summary table (no PMID printed)
• ATLS 10th/11th Ed. — as cited in the addendum summary table (no PMID printed)

Step 1: Contrast CT first to exclude strangulation, ischemia, perforation, peritonitis, closed-loop obstruction, or incarcerated hernia. Step 2: Nasogastric tube gastric decompression + aspiration/renal safety check before instilling 50–100 mL water-soluble contrast (Gastrografin) with abdominal radiograph at 8–24 hours. Step 3: Contrast in colon at 8–24 h predicts resolution (~96% sens/spec); failure of contrast to reach the colon at 24–36 hours is a high-risk prognostic indicator prompting formal surgical reassessment alongside clinical status — NOT an isolated automatic trigger for laparotomy in a clinically improving patient (where monitored observation up to a 72-hour ceiling may be considered; clinical deterioration or persistent obstruction >72 h mandates exploration).

Before: Administering Gastrografin before excluding strangulation/closed-loop obstruction or before nasogastric decompression, claiming contrast itself resolves obstruction, or treating 24-hour non-arrival in the colon as an automatic isolated trigger for laparotomy.

Now: Step 1: Contrast CT first to exclude strangulation, ischemia, perforation, peritonitis, closed-loop obstruction, or incarcerated hernia. Step 2: Nasogastric tube gastric decompression + aspiration/renal safety check before instilling 50–100 mL water-soluble contrast (Gastrografin) with abdominal radiograph at 8–24 hours. Step 3: Contrast in colon at 8–24 h predicts resolution (~96% sens/spec); failure of contrast to reach the colon at 24–36 hours is a high-risk prognostic indicator prompting formal surgical reassessment alongside clinical status — NOT an isolated automatic trigger for laparotomy in a clinically improving patient (where monitored observation up to a 72-hour ceiling may be considered; clinical deterioration or persistent obstruction >72 h mandates exploration).

Adults with suspected adhesive small bowel obstruction. Outcomes rated in the matrix: timely surgical intervention for ischemia/strangulation and prediction of non-operative resolution.

Contrast appearance in the colon within 8–24 hours is a prognostic indicator predicting non-operative resolution (~96% sensitivity and 96%–98% specificity) and shortens hospital stay, whereas randomized trials show mixed results on whether contrast independently lowers laparotomy rates. Always assess hemodynamic stability, peritonitis, and contrast-enhanced CT first to exclude closed-loop obstruction, bowel ischemia/strangulation, perforation, or incarcerated hernia before considering non-operative management; only in stable candidates selected for non-operative care, decompress the stomach via nasogastric tube, review aspiration risk, hydration, and contrast contraindications, and administer water-soluble contrast under a defined institutional protocol. Worsening pain, peritonitis, hemodynamic instability, or rising concern for ischemia mandates immediate surgery at any time (§4.0 Guardrail 1).

• WSES Bologna Adhesive Small Bowel Obstruction Guidelines — ten Broek et al., World J Emerg Surg 2018 (PMID 29946347)
• Abbas / Branco Meta-Analyses — as cited in Table 4.1

Prioritize immediate mechanical/surgical/endoscopic hemorrhage control and resuscitation without waiting for lab confirmation. Pair with drug-specific reversal per local hematology/transfusion protocol: Warfarin → 4-factor PCC (25–50 U/kg by INR/weight) + IV Vitamin K1 (5–10 mg); Dabigatran → idarucizumab 5 g IV; Factor Xa inhibitors (apixaban, rivaroxaban) → weigh bleeding severity, drug/last dose, renal function, thrombosis risk, and local availability (noting U.S. FDA Dec 18, 2025 safety communication and Dec 22, 2025 end of U.S. commercial sales of Andexxa vs. independent Saudi SFDA/local verification; many institutions use 4-factor PCC under local protocol).

Before: Delaying surgical/mechanical hemorrhage control while awaiting laboratory assays, presenting ANNEXA-I without its hemostatic efficacy endpoint, or stating U.S. FDA commercial status determines global availability or makes 4-factor PCC a universal substitute.

Now: Prioritize immediate mechanical/surgical/endoscopic hemorrhage control and resuscitation without waiting for lab confirmation. Pair with drug-specific reversal per local hematology/transfusion protocol: Warfarin → 4-factor PCC (25–50 U/kg by INR/weight) + IV Vitamin K1 (5–10 mg); Dabigatran → idarucizumab 5 g IV; Factor Xa inhibitors (apixaban, rivaroxaban) → weigh bleeding severity, drug/last dose, renal function, thrombosis risk, and local availability (noting U.S. FDA Dec 18, 2025 safety communication and Dec 22, 2025 end of U.S. commercial sales of Andexxa vs. independent Saudi SFDA/local verification; many institutions use 4-factor PCC under local protocol).

Patients with life-threatening hemorrhage on oral anticoagulants (ANNEXA-I enrolled acute intracerebral hemorrhage within 15 h of FXa inhibitor dose). Outcomes rated in the matrix: 12-h hemostatic efficacy, 30-d thrombosis, and mortality.

In ANNEXA-I (acute ICH on FXa inhibitors), andexanet improved 12-h hemostatic efficacy vs. usual care (85.5% PCC): 67.0% (150/224) vs. 53.1% (121/228) (adjusted difference +13.4%, 95% CI 4.6–22.2; P = 0.003), with no difference in 30-d mRS disability or overall 30-d death, but increased thrombotic events (10.3% [27/263] vs. 5.6% [15/267], P = 0.048 in NEJM safety cohort; 14.6% vs. 6.9% thrombosis and 2.5% vs. 0.9% day-30 thrombotic death in the full FDA safety review dataset). §7.0 Guardrail 3: where andexanet is unavailable or not selected, institutions may use 4-factor PCC under local hematology/transfusion protocol (weighing bleeding severity, drug/last dose, renal function, and thrombosis risk); 4-factor PCC is not a universal substitute and never replaces surgical/endoscopic hemorrhage control. §7.0 Guardrail 1: life-saving mechanical, surgical, or angiographic hemorrhage control and resuscitation must NEVER be delayed while waiting for laboratory coagulation, anti-Xa, or viscoelastic assay results.

Independent Saudi SFDA Regulatory Verification (§7.2 Saudi/GCC frame): U.S. FDA safety and commercial actions regarding andexanet alfa (Dec 2025) do not automatically govern Saudi Arabia; Saudi hospitals must verify current SFDA registration, local pharmacy formulary status, and institutional 4-factor PCC reversal protocols independently.

• ANNEXA-I RCT — Connolly et al., NEJM 2024 (PMID 38749032)
• U.S. FDA Safety Communication, Dec 18, 2025 — as cited in Table 7.1 (Ref. 69)

Keep splenic and hepatic pathways distinct and enforce institutional prerequisites (24/7 ICU, blood bank, OR, and interventional radiology): (A) Spleen: unstable → splenectomy; stable with CT arterial blush or pseudoaneurysm → urgent angioembolization; stable high-risk Grade III–V without initial blush → either prophylactic embolization or strict inpatient surveillance with mandatory day-5 CT and rescue embolization in resourced centers (SPLASH; favor prophylactic SAE if Grade IV–V, large hemoperitoneum, or uncertain follow-up/IR access); (B) Liver: unstable → damage-control perihepatic packing/Pringle maneuver; stable → NOM with selective angioembolization for arterial blush, ERCP/stenting for biliary leak, and drainage of biloma/hepatic necrosis.

Before: Equating 'stable for NOM' with 'low risk,' claiming >93% salvage applies universally outside protocolized Level I centers, or inferring from SPLASH that prophylactic embolization is never indicated.

Now: Keep splenic and hepatic pathways distinct and enforce institutional prerequisites (24/7 ICU, blood bank, OR, and interventional radiology): (A) Spleen: unstable → splenectomy; stable with CT arterial blush or pseudoaneurysm → urgent angioembolization; stable high-risk Grade III–V without initial blush → either prophylactic embolization or strict inpatient surveillance with mandatory day-5 CT and rescue embolization in resourced centers (SPLASH; favor prophylactic SAE if Grade IV–V, large hemoperitoneum, or uncertain follow-up/IR access); (B) Liver: unstable → damage-control perihepatic packing/Pringle maneuver; stable → NOM with selective angioembolization for arterial blush, ERCP/stenting for biliary leak, and drainage of biloma/hepatic necrosis.

Hemodynamically stable adults without peritonitis or hollow-viscus injury with blunt splenic (SPLASH / WSES) or hepatic trauma. Outcomes rated in the matrix: 1-month splenic salvage and organ preservation.

Hemodynamic stability + absence of peritonitis/hollow-viscus injury governs NOM in centers with 24/7 ICU, OR, and IR. SPLASH statistical & design boundary (Arvieux et al., JAMA Surg 2020): while 1-month vascularized splenic salvage was 98.2% (56/57 prophylactic SAE) vs. 93.3% (56/60 surveillance + rescue SAE; difference +4.9%, 95% CI −2.9% to +12.7%, p = 0.37), SPLASH was designed as a superiority trial rather than an equivalence trial, the wide 95% CI includes up to a 12.7% difference, and the surveillance arm had higher day-5 pseudoaneurysms (12.3% vs. 1.5%, p = 0.03) and required rescue embolization in 29.2% (19/65). §7.0 Guardrail 2: non-operative management of high-grade (AAST Grade III–V) splenic or hepatic trauma — and surveillance protocols such as SPLASH — are safe only in hospitals with continuous monitored/ICU care, immediate operating room and blood bank availability, serial CT capability, and 24/7 interventional radiology; in facilities lacking these capabilities, early surgical intervention or timely transfer is required. Unlike splenic trauma, high-grade liver injuries (AAST Grade III–V) carry specific risks of bile leak/biloma (~5%–20%), hemobilia, and hepatic necrosis (§7.2).

• SPLASH RCT — Arvieux et al., JAMA Surg 2020 (PMID 32936242)
• WSES Spleen Trauma Guidelines (PMID 28828034)
• WSES Liver Trauma Guidelines — as cited in Table 7.1

Calculate %TBSA using the Lund-Browder chart or Rule of Nines (counting ONLY deep partial-thickness [2nd degree] and full-thickness [3rd degree] burns; exclude superficial 1st-degree erythema). Initiate ABA-modified fluid resuscitation for thermal burns ≥20% TBSA at 2 mL/kg/%TBSA of warmed Lactated Ringer's (4 mL/kg/%TBSA reserved for high-voltage electrical injuries with myoglobinuria), giving half over the first 8 hours from time of burn and titrating hourly to urine output 0.5–1.0 mL/kg/h (30–50 mL/h in adults; 1.0–1.5 mL/kg/h in electrical myoglobinuria). Perform immediate bedside longitudinal escharotomy for circumferential full-thickness limb or thoracic eschar restricting perfusion/ventilation, and perform early tangential excision and split-thickness autografting within 24–72 hours (using topical 1% silver sulfadiazine or nanocrystalline silver dressings without prophylactic systemic antibiotics).

Before: Unmonitored 4 mL/kg/%TBSA Parkland crystalloid boluses causing massive 'fluid creep' abdominal/extremity compartment syndrome, prophylactic systemic antibiotics, or delayed eschar separation by secondary sloughing.

Now: Calculate %TBSA using the Lund-Browder chart or Rule of Nines (counting ONLY deep partial-thickness [2nd degree] and full-thickness [3rd degree] burns; exclude superficial 1st-degree erythema). Initiate ABA-modified fluid resuscitation for thermal burns ≥20% TBSA at 2 mL/kg/%TBSA of warmed Lactated Ringer's (4 mL/kg/%TBSA reserved for high-voltage electrical injuries with myoglobinuria), giving half over the first 8 hours from time of burn and titrating hourly to urine output 0.5–1.0 mL/kg/h (30–50 mL/h in adults; 1.0–1.5 mL/kg/h in electrical myoglobinuria). Perform immediate bedside longitudinal escharotomy for circumferential full-thickness limb or thoracic eschar restricting perfusion/ventilation, and perform early tangential excision and split-thickness autografting within 24–72 hours (using topical 1% silver sulfadiazine or nanocrystalline silver dressings without prophylactic systemic antibiotics).

Acute thermal and high-voltage electrical burn resuscitation, escharotomy, and early tangential excision.

Starting at 2 mL/kg/%TBSA and titrating strictly to hourly urine output prevents over-resuscitation ('fluid creep'), pulmonary edema, and secondary abdominal/orbital compartment syndrome; early tangential excision and grafting within 72 hours halves burn wound sepsis and hospital length of stay.

Saudi & Gulf frame (§12.0): regional burn centers address severe full-thickness infected burns and necrotizing cellulitis resulting from traditional heated-metal cautery ('Kaiy') applied over abdominal, spinal, or neuropathic limb pain.

• American Burn Association (ABA) Clinical Practice Guidelines (2023/2024) — as cited in Addendum §12.1
• ISBI Practice Guidelines — as cited in Addendum §12.1

Initiate early balanced 1:1:1 component transfusion (plasma : platelets : RBCs; PROPPR) or cold-stored Low-Titer Group O Whole Blood (LTOWB) where approved by local blood-bank inventory, while achieving definitive surgical/angiographic hemostasis.

Before: Sequential crystalloid and unguided packed red blood cell transfusion before plasma and platelet replacement.

Now: Initiate early balanced 1:1:1 component transfusion (plasma : platelets : RBCs; PROPPR) or cold-stored Low-Titer Group O Whole Blood (LTOWB) where approved by local blood-bank inventory, while achieving definitive surgical/angiographic hemostasis.

Severely injured trauma patients predicted to require massive transfusion (PROPPR n = 680). Outcomes rated in the matrix: 24-h/30-d all-cause mortality (co-primary) and anatomic hemostasis / 24-h exsanguination death (secondary).

In PROPPR (n = 680), co-primary 24-h mortality (12.7% vs. 17.0%, p = 0.12) and 30-d mortality (22.4% vs. 26.1%, p = 0.26) did not reach statistical significance, whereas secondary anatomic hemostasis (86.1% vs. 78.1%, p = 0.006) and 24-h exsanguination death (9.2% vs. 14.6%, p = 0.03) favored 1:1:1. LTOWB is unbundled because PROPPR evaluated component ratios, not whole blood. Secondary hemostasis findings must never be misstated as proven overall mortality superiority, and implementation requires institutional blood-bank massive transfusion protocol (MTP) capability (§7.2).

• PROPPR Randomized Trial — Holcomb et al., JAMA 2015 (PMID 25647203)

Monitor arterial ionized calcium every 30–60 minutes during massive transfusion and administer salt-specific IV calcium when ionized calcium falls <1.0–1.1 mmol/L (1 g 10% calcium chloride via central access [= 270 mg elemental Ca] OR 2–3 g 10% calcium gluconate IV [= 180–270 mg elemental Ca]).

Before: Empiric massive blood-product transfusion without serial ionized calcium monitoring or salt-specific dosing.

Now: Monitor arterial ionized calcium every 30–60 minutes during massive transfusion and administer salt-specific IV calcium when ionized calcium falls <1.0–1.1 mmol/L (1 g 10% calcium chloride via central access [= 270 mg elemental Ca] OR 2–3 g 10% calcium gluconate IV [= 180–270 mg elemental Ca]).

Trauma patients receiving rapid citrated blood-product transfusion. Outcome rated in the matrix: prevention of ionized hypocalcemia (<1.0–1.1 mmol/L)-induced coagulopathy and myocardial depression.

This row is unbundled from PROPPR and CRASH-2 because ionized calcium replacement is anchored in biochemical citrate-chelation physiology and observational MTP cohorts rather than a Phase III randomized trial: observational trauma cohorts show an independent association of iCa <1.0 mmol/L with coagulopathy and mortality, and there is no randomized calcium-threshold trial (matrix rating basis).

• European Trauma Coagulopathy Guidelines — as cited in Table 7.1
• Military / Civilian MTP Consensus — as cited in Table 7.1

Do not use routine Emergency Department REBOA where deployment may delay definitive surgical or endovascular hemorrhage control (UK-REBOA setting). Any selective use as an immediate bridge in an operating room or hybrid trauma suite requires strict institutional prerequisites: experienced credentialed team, continuous arterial pressure monitoring, immediate definitive hemostasis readiness, and strict occlusion-time governance.

Before: Broad empiric deployment of Emergency Department REBOA without immediate definitive surgical/angiographic hemorrhage control, or issuing a setting-blind ban that ignores system context.

Now: Do not use routine Emergency Department REBOA where deployment may delay definitive surgical or endovascular hemorrhage control (UK-REBOA setting). Any selective use as an immediate bridge in an operating room or hybrid trauma suite requires strict institutional prerequisites: experienced credentialed team, continuous arterial pressure monitoring, immediate definitive hemostasis readiness, and strict occlusion-time governance.

Adults with confirmed/suspected life-threatening torso hemorrhage in the emergency department (UK-REBOA) vs. immediate operating-room/hybrid-suite settings. Outcomes rated in the matrix: 90-day mortality and time to definitive hemostasis.

In UK-REBOA (n = 90 across 16 UK major trauma centers: 46 REBOA + standard care vs. 44 standard care alone), 90-day all-cause mortality was 54% (25/46) vs. 42% (18/43) (OR 1.58, 95% credible interval 0.72–3.52; 86.9% posterior probability of increased mortality), and median time from randomization to definitive hemorrhage control was 19 minutes longer in the REBOA group. §7.2 states the retained selective pathway's prerequisites in full: credentialed vascular/trauma operators with ongoing femoral-access competency, invasive arterial pressure monitoring, immediate availability of definitive surgical/angiographic hemorrhage control in the same or adjacent room, strict ischemia/occlusion-time limits (e.g., <=30 min Zone 1, <=60 min Zone 3), and formal institutional audit governance. §7.0 Guardrail 2: routine Emergency Department REBOA is not recommended in settings where it delays definitive hemostasis.

• UK-REBOA Bayesian RCT — Jansen et al., JAMA 2023 (PMID 37824132)

SSRF within 48–72 h is supported for clinical flail chest (>=3 consecutive ribs fractured in >=2 places) with respiratory failure/ventilator dependence (and selectively in severe displaced non-flail fractures with refractory chest-wall instability/pain). Trigger DCL using integrated physiological exhaustion indicators (hypothermia, acidosis, coagulopathy, ionized hypocalcemia) + anatomical complexity. Diagnose extremity compartment syndrome primarily by serial clinical examination (pain out of proportion, pain on passive stretch, tense compartment), integrating compartment manometry (Delta Pressure = Diastolic BP minus Compartment Pressure <=30 mmHg) in obtunded or equivocal patients.

Before: Implying every radiographic flail segment requires SSRF, treating the 'lethal diamond' mnemonic as a validated numerical score, or relying on a single compartment pressure number in isolation.

Now: SSRF within 48–72 h is supported for clinical flail chest (>=3 consecutive ribs fractured in >=2 places) with respiratory failure/ventilator dependence (and selectively in severe displaced non-flail fractures with refractory chest-wall instability/pain). Trigger DCL using integrated physiological exhaustion indicators (hypothermia, acidosis, coagulopathy, ionized hypocalcemia) + anatomical complexity. Diagnose extremity compartment syndrome primarily by serial clinical examination (pain out of proportion, pain on passive stretch, tense compartment), integrating compartment manometry (Delta Pressure = Diastolic BP minus Compartment Pressure <=30 mmHg) in obtunded or equivocal patients.

Adults with clinical/ventilator-dependent flail chest vs. non-flail displaced rib fractures; exsanguinating abdominal trauma ('lethal diamond'); and extremity trauma at risk for compartment syndrome. Outcomes rated in the matrix: ventilator days, tracheostomy and pneumonia (SSRF); compartment perfusion against the Delta Pressure threshold (compartment syndrome).

In flail chest with mechanical ventilation (Marasco et al., Dehghan et al. RCTs), SSRF reduced ventilator days, tracheostomy, and pneumonia, whereas in non-flail displaced fractures (Pieracci et al.), benefit is limited to pain/pleural space outcomes. In compartment syndrome, perfusion depends on diastolic driving pressure (Delta Pressure <=30 mmHg; McQueen & Court-Brown 1996) paired with clinical trajectory. §7.2 states the DCL trigger set in full: the 'Lethal Diamond' (hypothermia, metabolic acidosis, coagulopathy, citrate-induced ionized hypocalcemia) is a physiological resuscitation framework rather than a single validated scoring rule; trigger DCL by integrating physiological exhaustion (e.g., core temperature <34–35°C, arterial pH <7.20, base deficit >6–8 mmol/L, clinical/viscoelastic coagulopathy, ionized calcium <1.0 mmol/L, or massive transfusion) with injury complexity. §7.2 likewise keeps radiographic flail segments without respiratory compromise distinct from clinical flail chest with respiratory failure or ventilator dependence.

• CWIS / EAST Rib Fixation Guidelines (Pieracci et al., Dehghan et al. RCTs) — as cited in Table 7.1
• WSES Open Abdomen Guidelines — as cited in Table 7.1
• McQueen & Court-Brown, J Bone Joint Surg Br 1996 — as cited in Table 7.1

Administer IV Tranexamic Acid (1 g over 10 min + 1 g over 8 h) strictly within 3 hours of injury in patients with clinically significant extracranial hemorrhage (CRASH-2) and in selected patients with mild-to-moderate TBI (GCS 9–15) within 3 hours (CRASH-3).

Before: Delayed TXA administration (>3 hours after injury) or uniform extrapolation across all TBI severities.

Now: Administer IV Tranexamic Acid (1 g over 10 min + 1 g over 8 h) strictly within 3 hours of injury in patients with clinically significant extracranial hemorrhage (CRASH-2) and in selected patients with mild-to-moderate TBI (GCS 9–15) within 3 hours (CRASH-3).

Bleeding trauma patients within 3 h (CRASH-2 n = 20,211) vs. acute TBI within 3 h (CRASH-3 n = 9,202). Outcomes rated in the matrix: 28-day bleeding mortality (CRASH-2) and 28-day head-injury mortality in GCS 9–15 vs. GCS 3–8 (CRASH-3).

In CRASH-2, TXA <=1 h (RR 0.68) and 1–3 h (RR 0.79) reduced bleeding death, whereas initiation >3 h increased bleeding mortality (RR 1.44). In CRASH-3, severe TBI (GCS 3–8) showed no benefit (RR 0.99); the overall CRASH-3 primary endpoint was neutral (18.5% vs. 19.8%, RR 0.94, 95% CI 0.86–1.02) and benefit was confined to the prespecified mild-to-moderate GCS 9–15 subgroup (RR 0.78, 95% CI 0.64–0.95). CRASH-3 enrolled isolated TBI (GCS <=12 or intracranial bleeding on CT, no major extracranial hemorrhage) — do not merge the two trials into one indication (§7.2).

• CRASH-2 RCT (PMID 20554319)
• CRASH-3 RCT (PMID 31623894)

Use separate injury-specific hemodynamic targets: (1) In penetrating/blunt torso hemorrhage WITHOUT TBI, restrict crystalloids and use temporary permissive hypotension (target SBP 80–90 mmHg / MAP 50–60 mmHg) strictly as a brief bridge to surgical/endovascular hemostasis; (2) In suspected or confirmed Traumatic Brain Injury (or spinal cord injury), permissive hypotension is contraindicated — maintain SBP >=100 mmHg (ages 50–69) or >=110 mmHg (ages 15–49 or >70; MAP >=80 mmHg).

Before: Applying a single universal blood-pressure target (or aggressive 2-L crystalloid boluses) to all trauma patients regardless of brain injury status.

Now: Use separate injury-specific hemodynamic targets: (1) In penetrating/blunt torso hemorrhage WITHOUT TBI, restrict crystalloids and use temporary permissive hypotension (target SBP 80–90 mmHg / MAP 50–60 mmHg) strictly as a brief bridge to surgical/endovascular hemostasis; (2) In suspected or confirmed Traumatic Brain Injury (or spinal cord injury), permissive hypotension is contraindicated — maintain SBP >=100 mmHg (ages 50–69) or >=110 mmHg (ages 15–49 or >70; MAP >=80 mmHg).

Adults in hemorrhagic shock without brain injury vs. patients with suspected/confirmed TBI (GCS <=12 or intracranial bleeding). Outcome rated in the matrix: prevention of secondary ischemic brain mortality vs. hydrostatic clot disruption.

Unbundling hemodynamic targets from blood-product ratios is essential because a single episode of SBP <90 mmHg in TBI causes secondary cerebral ischemia and doubles mortality, whereas excessive crystalloid hydrostatic pressure in non-TBI cavitary hemorrhage disrupts early clot formation. §7.0 Guardrail 1 restates the same boundary: do not apply permissive hypotension (SBP 80–90 mmHg) to patients with suspected or confirmed TBI or spinal cord injury, where maintaining SBP >=100–110 mmHg (MAP >=80 mmHg) is essential to preserve cerebral perfusion.

• ATLS 10th Edition — as cited in Table 7.1
• Brain Trauma Foundation / WSES Guidelines — as cited in Table 7.1

Laparoscopic appendectomy remains definitive standard treatment; antibiotic-first therapy is a shared-decision option for appropriately selected adults after discussing appendicolith status on CT, initial treatment failure vs. later recurrence, need for subsequent appendectomy, and adverse events.

Before: Describing antibiotic-first therapy as universally equivalent to appendectomy across all uncomplicated appendicitis, or pooling CODA and APPAC into a single undifferentiated failure rate.

Now: Laparoscopic appendectomy remains definitive standard treatment; antibiotic-first therapy is a shared-decision option for appropriately selected adults after discussing appendicolith status on CT, initial treatment failure vs. later recurrence, need for subsequent appendectomy, and adverse events.

Adults with imaging-confirmed (CT-confirmed) uncomplicated acute appendicitis. Outcomes rated in the matrix: initial treatment failure, subsequent recurrence, cumulative appendectomy, and complications.

In CODA (PMID 33017106; Ref. 26; n = 1,552), 90-day appendectomy was 41% with an appendicolith vs. 25% without (rising to 40% at 1 yr and 46% at 2 yrs overall), with higher complications in the appendicolith subgroup (20.2 vs. 3.6 per 100). CODA showed non-inferior 30-day EQ-5D health status, but cumulative appendectomy in the antibiotic arm was 29% at 90 days. In APPAC II (Sippola et al., JAMA 2021; PMID 33427870; Ref. 27; n = 599 appendicolith-free adults), 1-year success was 70.2% with 7-day oral moxifloxacin vs. 73.8% with IV ertapenem + oral levofloxacin/metronidazole, which narrowly missed the prespecified −6.0% non-inferiority margin (difference −3.6%, 1-sided 95% CI −9.7%, p = 0.26). In APPAC 10-year follow-up (PMID 26080338; Ref. 57), true recurrence was 37.8% (44.3% cumulative appendectomy).

• CODA Trial, NEJM 2020/2021 (PMID 33017106)
• APPAC Trial — Salminen et al., JAMA 2015 (PMID 26080338)
• APPAC II Trial — Sippola et al., JAMA 2021 (PMID 33427870)